Pine Bark Extract

Pine Bark Extract

Main Active Ingredients:
Oligomeric Proanthocyanidins (OPCs) – CAS: 133248-87-0｜Assay: 85–95% by HPLC (typical 95%)
Application: antioxidant & cardiovascular-wellness supplements, cosmeceutical & nutricosmetic actives, functional foods & beverages, sports-nutrition formulations
MOQ: 1KG｜US Warehouse Stock Available — ships within 2 business days for US customers
Certifications: ISO, HACCP, GMP, Kosher, Halal, Organic, BRC, FDA Registered Facility

Send Inquiry

Thank you for sharing our article through the button

Facebook
X
LinkedIn
Telegram
Reddit

Pine Bark Extract Supplier (Pinus pinaster): 85–95% OPCs, Multi-System Research & B2B Sourcing Guide

Written by Jonathan, Valeherb · Reviewed by Dr. Xiaoyan Qiu · Updated April 2026

Not all pine bark extracts are equivalent — the published research that makes this ingredient notable is built on a specific species and extraction standard. Standardized Pinus pinaster bark extract, sourced from French maritime pine and standardized to 85–95% oligomeric proanthocyanidins (OPCs), is one of the most extensively researched botanical ingredients in the supplement industry. With a large published literature base and research spanning cardiovascular, cognitive, dermatological, and metabolic pathways, it occupies a rare position: a single-origin botanical with a multi-system research base relevant to a broad range of formulation categories.

Active Compounds: OPCs and Why Standardization Matters

The bioactive fraction of pine bark extract is a class of polyphenols called Oligomeric Proanthocyanidins (OPCs) — flavonoid complexes comprising catechin, epicatechin, and their oligomeric forms. OPC concentration and structural integrity directly determine batch consistency: low-grade extracts with variable OPC content produce inconsistent results and cannot provide a defined, defensible specification.

Compound Class Standardization Target Activity Studied in Research
Oligomeric Proanthocyanidins (OPCs) 85–95% by HPLC[1] Antioxidant activity (reported in published assays to exceed vitamin C and vitamin E in some measures); inflammatory-pathway (NF-κB) research; vascular endothelium research
Procyanidins (Catechin / Epicatechin oligomers) Subset of OPC fraction Studied for collagen cross-linking, MMP inhibition, and endothelial nitric oxide (NO) production[2]
Phenolic Acids (Ferulic, Caffeic) Minor fraction Synergistic antioxidant activity; UV-photoprotection research in topical applications
SOURCING NOTE
A common procurement inquiry is for “pine bark extract” without species specification. This is a critical gap: OPC profiles differ significantly between Pinus pinaster (French maritime pine), Pinus radiata, and generic pine species. The published clinical database — including trials on the proprietary Pycnogenol® extract — is built almost entirely on Pinus pinaster from southwest France, and that clinical data attaches to the specific extract studied. An extract from a different species, or a different specification, cannot claim equivalence to that literature. Always specify Pinus pinaster and request origin documentation alongside the COA.

Areas of Published Research

NOTE
The research summarised below characterises the activity of Pinus pinaster OPCs and specific studied extracts (often the proprietary Pycnogenol®), for informational purposes only. It is not a claim for any Valeherb product. Any claim on a finished product is the marketer’s responsibility to substantiate against the actual material used.

Pinus pinaster bark extract is one of the few botanical ingredients studied across multiple systems in peer-reviewed research:

Research Area Mechanism Studied Reported in Research
Cardiovascular Endothelial NO production; LDL-oxidation; platelet aggregation[2] Reductions in LDL oxidation and modest changes in blood-pressure measures across study participants in multiple RCTs
Skin & Anti-Aging MMP inhibition (collagen and elastin); UV-induced ROS scavenging[3] Improved skin elasticity and hydration, reduced UV photoaging markers in controlled trials
Inflammatory-Pathway NF-κB pathway; prostaglandin synthesis[5] Reductions in CRP and inflammatory-marker levels in research
Cognitive Cerebral microcirculation via NO-mediated vasodilation[4] Measurable changes in attention and working memory in aging study populations
Glucose Metabolism Alpha-glucosidase inhibition; insulin-receptor research Effects on postprandial glucose markers in metabolic research
Joint Comfort IL-1β and TNF-α modulation; cartilage research[1] Improved mobility scores in joint-comfort research
Histamine Response Mast-cell stabilization; histamine-release inhibition Reductions in symptom-severity scores in seasonal histamine-response research

Doses Used in Published Research

Research Context Dose Used in Trials Basis
Antioxidant / general 50 mg/day Entry-level dose used in maintenance trials[1]
Cardiovascular / cognitive research 100–150 mg/day Most commonly used range in cardiovascular and cognitive RCTs[2]
Joint-comfort research 150–200 mg/day Dose range used in mobility trials[1]
Metabolic research 200–300 mg/day Higher-dose range from metabolic-research trials

The figures above are doses used in published research, provided as a formulation reference only — not treatment recommendations or dosing instructions for any condition. Finished-product dosing and claims are the marketer’s responsibility under applicable regulations.

FORMULATION NOTE
When clients formulate multi-ingredient supplements combining pine bark extract with other antioxidants (vitamin C, vitamin E, resveratrol), we advise specifying OPC content rather than extract weight alone. A 100 mg dose of 90% OPC extract and a 100 mg dose of 50% OPC extract deliver very different active-compound levels — yet both can appear identical on a label. OPC percentage on the COA is the only reliable basis for inter-batch consistency.

Formulation Applications

  • Nutraceuticals (capsules/tablets): 50–200 mg standardized extract per serving covers the full research dose range. Pairs with vitamin C (OPC-vitamin C regeneration cycle), CoQ10, and resveratrol in cardiovascular and antioxidant formulations
  • Cosmeceuticals (topical): MMP-inhibition and UV-photoprotection research are directly applicable to anti-aging serums and eye creams. Water-soluble OPC fraction required for aqueous emulsion systems; stable at standard cosmetic pH ranges
  • Functional beverages: Water-soluble pine bark extract grades dissolve cleanly in RTD formats without sedimentation. Mild astringency at higher concentrations manageable with natural flavor masking; no significant color interference in clear formats
  • Sports nutrition: Vascular and endothelial NO-production research supports the blood-flow and recovery category; non-stimulant, WADA-compliant ingredient for pre-workout and recovery formulas
  • Women’s-health supplements: An emerging research area; pine bark extract is studied in women’s-health contexts and is used as an active in that formulation category

Sourcing Criteria: What Every B2B Buyer Should Require

Criterion What to Require
Species Specification Pinus pinaster only — not generic “pine bark.” Request botanical identity documentation and origin certificate
OPC Standardization 85–95% OPC content by HPLC per batch — the benchmark for clinical-trial-equivalent specifications
Extraction Method Aqueous (water-based) extraction preferred to preserve OPC chain integrity without solvent residues. Confirm solvent-free status or solvent-residue testing on the COA
Third-Party COA OPC content (HPLC), heavy metals (USP <232>), pesticide residues, microbial limits (USP <2021>), residual solvents, moisture — per production batch
USP / Ph. Eur. Compliance Relevant for pharmaceutical-use supply chains. Request monograph compliance documentation if required by your regulatory pathway
Certifications Non-GMO, Kosher/Halal for relevant markets. FDA-registered facility required for US supplement supply chains
CAUTION
Pine bark extract has a well-established tolerability profile in published literature. The most commonly reported adverse effects — mild gastrointestinal discomfort, nausea, or headache — are dose-dependent and typically occur above 300 mg/day. OPCs have mild anticoagulant properties; concomitant use with warfarin, aspirin, or other blood thinners warrants precautionary label disclosure. Theoretical interactions with immunosuppressants have been noted. Not recommended during pregnancy or breastfeeding due to insufficient controlled clinical data. Generally considered well-tolerated for long-term use at recommended doses in healthy adults.

Regulatory Guidance

FDA NOTICE
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. Required for all dietary supplement products sold in the United States.
  • US (DSHEA): Any structure/function claim on the finished product is the marketer’s responsibility to substantiate and must carry the FDA disclaimer; antioxidant claims are the most readily supported. Cardiovascular, cognitive, and joint claims sit closer to disease territory and need careful wording. Blood-sugar claims in particular require careful framing — “supports healthy blood glucose levels already within the normal range” is the appropriate structure/function wording. Disease treatment claims require drug (NDA) approval
  • EU: OPCs are not currently on the EU authorized health claims register as a standalone ingredient. Antioxidant claims under EC 1924/2006 require specific substance authorization. Consult regulatory counsel for current status in target EU markets
  • Canada (NHPs): Pine bark extract has a licensed Health Canada monograph supporting antioxidant and cardiovascular claims under Natural Health Products Regulations (regulatory background for buyers)

References

[1] Weichmann F & Rohdewald P. (2024). Pycnogenol® French maritime pine bark extract in randomized, double-blind, placebo-controlled human clinical studies. Frontiers in Nutrition, 11, 1389374. PMID: 38757130

[2] Enseleit F et al. (2012). Effects of Pycnogenol on endothelial function in patients with stable coronary artery disease: a double-blind, randomized, placebo-controlled, cross-over study. European Heart Journal, 33(13), 1589–1597. doi:10.1093/eurheartj/ehr482

[3] Marini A et al. (2012). Pycnogenol effects on skin elasticity and hydration coincide with increased gene expressions of collagen type I and hyaluronic acid synthase in women. Skin Pharmacology and Physiology, 25(2), 86–92. doi:10.1159/000335261

[4] Ryan J et al. (2008). An examination of the effects of the antioxidant Pycnogenol on cognitive performance, serum lipid profile, endocrinological and oxidative stress biomarkers in an elderly population. Journal of Psychopharmacology, 22(5), 553–562. PMID: 18701642

[5] Grimm T et al. (2006). Inhibition of NF-κB activation and MMP-9 secretion by plasma of human volunteers after ingestion of maritime pine bark extract (Pycnogenol). Journal of Inflammation, 3, 1. doi:10.1186/1476-9255-3-1

Reviewed byDr. Xiaoyan QiuBotanical Extract R&D Engineer · Associate Professor, Huaihua University. Research focus: medicinal plant resources, botanical extraction processes, and microbial fermentation technology — directly relevant to polyphenol/OPC extract characterisation.
Written byJonathanContent Editor, Valeherb. Specializing in botanical ingredient science communication for B2B nutraceutical and functional food markets.

Disclaimer: This article is intended for informational purposes only. All research referenced cites published peer-reviewed literature and is not intended as medical advice. These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. Products must comply with applicable regulations in the buyer’s jurisdiction. © 2026 Valeherb. All rights reserved.

FAQ

A1:No. The OPC profile differs significantly between Pinus pinaster (French maritime pine), Pinus radiata, and generic pine species, and the published clinical database — including the proprietary Pycnogenol® trials — is built almost entirely on Pinus pinaster from southwest France. That clinical data attaches to the specific extract studied, so an extract from a different species or specification cannot claim equivalence to that literature. Always specify Pinus pinaster and require botanical-identity and origin documentation alongside the COA.
A2:Because two extracts at the same milligram weight can deliver very different active-compound loads. A 100 mg dose of 90% OPC extract and a 100 mg dose of 50% OPC extract look identical on a label but are not equivalent in OPC content. Valeherb standardizes to 85–95% OPCs by HPLC, and you should require the OPC percentage on a batch-specific COA — it is the only reliable basis for inter-batch consistency and accurate label specification.
A3:Aqueous (water-based) extraction is preferred because it preserves OPC chain integrity without solvent residues; confirm solvent-free status or solvent-residue testing on the COA. Beyond OPC content by HPLC, require a per-batch third-party COA covering heavy metals, pesticide residues, microbial limits, residual solvents, and moisture, plus species and origin documentation. For pharmaceutical-use supply chains, request USP or Ph. Eur. monograph compliance documentation.
A4:Any structure/function claim is the marketer’s responsibility to substantiate and must carry the FDA disclaimer in the US; antioxidant claims are the most readily supported area. Cardiovascular, cognitive, and joint claims sit closer to disease territory and need careful wording, and blood-sugar claims in particular should use framing such as “supports healthy blood glucose levels already within the normal range.” Disease treatment claims require drug approval. Canada has a licensed monograph for antioxidant and cardiovascular claims, while the EU does not currently authorize standalone OPC health claims, so confirm the framework for your target market.

Related products

SEND INQUIRY

Contact Form Demo
Mogroside V: Grades, Stability and Performance Guide

The essence of natural sweetness — extracted directly from plants

monk fruit extract-mogroside V
Trilobatin Inclusion Rate and Blend Systems

The most promising sugar-free and zero-calorie sweetener usage guide for 2026

Trilobatin Inclusion Rate
The 7 Best Zero-Calorie Sweeteners

Understand the gap between natural sweeteners and synthetic sweeteners

Zero-Calorie Sweeteners